CA2468839A1 - Methods of treating cancer using an fpt inhibitor and anti neoplastic agents - Google Patents
Methods of treating cancer using an fpt inhibitor and anti neoplastic agents Download PDFInfo
- Publication number
- CA2468839A1 CA2468839A1 CA002468839A CA2468839A CA2468839A1 CA 2468839 A1 CA2468839 A1 CA 2468839A1 CA 002468839 A CA002468839 A CA 002468839A CA 2468839 A CA2468839 A CA 2468839A CA 2468839 A1 CA2468839 A1 CA 2468839A1
- Authority
- CA
- Canada
- Prior art keywords
- administered
- amount
- day
- fpt inhibitor
- twice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33441101P | 2001-11-30 | 2001-11-30 | |
| US60/334,411 | 2001-11-30 | ||
| PCT/US2002/037954 WO2003047697A2 (en) | 2001-11-30 | 2002-11-25 | Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2468839A1 true CA2468839A1 (en) | 2003-06-12 |
Family
ID=23307076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002468839A Abandoned CA2468839A1 (en) | 2001-11-30 | 2002-11-25 | Methods of treating cancer using an fpt inhibitor and anti neoplastic agents |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20030185831A1 (https=) |
| EP (1) | EP1448268A2 (https=) |
| JP (1) | JP2005511663A (https=) |
| CN (2) | CN1617755A (https=) |
| AU (1) | AU2002352941A1 (https=) |
| BR (1) | BR0214564A (https=) |
| CA (1) | CA2468839A1 (https=) |
| HU (1) | HUP0402401A2 (https=) |
| MX (1) | MXPA04005207A (https=) |
| NO (1) | NO20042730L (https=) |
| NZ (1) | NZ532562A (https=) |
| WO (1) | WO2003047697A2 (https=) |
| ZA (1) | ZA200403737B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005533838A (ja) * | 2002-07-24 | 2005-11-10 | ノバルティス アクチエンゲゼルシャフト | 未分化甲状腺癌を処置するための４−（４−メチルピペラジン−１−イルメチル）−ｎ−［４−メチル−３−（４−ピリジン−３−イル）ピリミジン−２−イルアミノ］フェニル］−ベンズアミド |
| CA2439440A1 (en) * | 2002-09-05 | 2004-03-05 | Emory University | Treatment of tuberous sclerosis associated neoplasms |
| CA2544421A1 (en) * | 2003-11-06 | 2005-05-26 | Schering Corporation | Combination of a farnesyl transferase inhibitor with an antihormonal agent for the treatment of breast cancer |
| JP2007525507A (ja) * | 2004-02-26 | 2007-09-06 | ザ ペン ステイト リサーチ ファンデーション | オピオイド増殖因子レセプターを用いる、新生物の処置のための組み合わせ療法 |
| US20060205810A1 (en) * | 2004-11-24 | 2006-09-14 | Schering Corporation | Platinum therapeutic combinations |
| US20080255171A1 (en) * | 2005-10-07 | 2008-10-16 | Manley Paul W | Combination of Nilotinib with Farnesyl Transferase Inhibitors |
| WO2008051531A2 (en) * | 2006-10-25 | 2008-05-02 | Schering Corporation | Discontinuous methods of treating cancer |
| WO2008067144A2 (en) * | 2006-11-28 | 2008-06-05 | Smithkline Beecham (Cork) Limited | Cancer treatment method |
| US20230390197A1 (en) * | 2020-10-27 | 2023-12-07 | Wisconsin Alumni Research Foundation | Modular dendron micelles for combination immunotherapy |
| AU2023376684A1 (en) | 2022-11-09 | 2025-06-19 | Merck Patent Gmbh | Toll-like receptor 7 agonists as immune-stimulators to elicit the innate antitumor immunity |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874442A (en) * | 1995-12-22 | 1999-02-23 | Schering-Plough Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease |
| US6096757A (en) * | 1998-12-21 | 2000-08-01 | Schering Corporation | Method for treating proliferative diseases |
| DK1041985T3 (da) * | 1997-12-22 | 2006-06-19 | Schering Corp | Kombination af benzocycloheptapyridinforbindelser og antineoplastiske lægemidler til behandling af profilerative sygdomme |
| US6316462B1 (en) * | 1999-04-09 | 2001-11-13 | Schering Corporation | Methods of inducing cancer cell death and tumor regression |
| JP5491681B2 (ja) * | 2000-02-04 | 2014-05-14 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 乳ガンの治療のためのファルネシルタンパク質トランスフェラーゼ阻害剤 |
| US6838467B2 (en) * | 2000-02-24 | 2005-01-04 | Janssen Pharmaceutica N. V. | Dosing regimen |
| CA2397448A1 (en) * | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with further anti-cancer agents |
| JP2003525239A (ja) * | 2000-02-29 | 2003-08-26 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | タキサン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤 |
| AR033680A1 (es) * | 2000-08-30 | 2004-01-07 | Schering Corp | Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales |
| EP1322334A2 (en) * | 2000-10-05 | 2003-07-02 | George Q. Daley | Methods of inducing cancer cell death and tumor regression |
-
2002
- 2002-11-25 CN CNA028239202A patent/CN1617755A/zh active Pending
- 2002-11-25 AU AU2002352941A patent/AU2002352941A1/en not_active Abandoned
- 2002-11-25 HU HU0402401A patent/HUP0402401A2/hu unknown
- 2002-11-25 MX MXPA04005207A patent/MXPA04005207A/es unknown
- 2002-11-25 CA CA002468839A patent/CA2468839A1/en not_active Abandoned
- 2002-11-25 US US10/303,259 patent/US20030185831A1/en not_active Abandoned
- 2002-11-25 EP EP02789901A patent/EP1448268A2/en not_active Withdrawn
- 2002-11-25 NZ NZ532562A patent/NZ532562A/en unknown
- 2002-11-25 CN CNA2007101860344A patent/CN101181269A/zh active Pending
- 2002-11-25 WO PCT/US2002/037954 patent/WO2003047697A2/en not_active Ceased
- 2002-11-25 JP JP2003548949A patent/JP2005511663A/ja not_active Withdrawn
- 2002-11-25 BR BR0214564-2A patent/BR0214564A/pt not_active IP Right Cessation
-
2004
- 2004-05-14 ZA ZA200403737A patent/ZA200403737B/en unknown
- 2004-06-29 NO NO20042730A patent/NO20042730L/no not_active Application Discontinuation
-
2006
- 2006-04-03 US US11/396,892 patent/US20060183765A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NO20042730L (no) | 2004-06-29 |
| WO2003047697A2 (en) | 2003-06-12 |
| AU2002352941A1 (en) | 2003-06-17 |
| ZA200403737B (en) | 2005-05-23 |
| WO2003047697A3 (en) | 2003-10-30 |
| MXPA04005207A (es) | 2004-08-19 |
| US20060183765A1 (en) | 2006-08-17 |
| JP2005511663A (ja) | 2005-04-28 |
| HUP0402401A2 (hu) | 2005-03-29 |
| EP1448268A2 (en) | 2004-08-25 |
| CN101181269A (zh) | 2008-05-21 |
| NZ532562A (en) | 2007-02-23 |
| US20030185831A1 (en) | 2003-10-02 |
| CN1617755A (zh) | 2005-05-18 |
| BR0214564A (pt) | 2004-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4506004A1 (en) | Pharmaceutical composition, use thereof, and method for treating cancer | |
| EP2127652B1 (en) | Method for treating cancer using anticancer agent in combination | |
| EP2501385B1 (en) | Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent | |
| TW200533339A (en) | Therapeutic synergy of anti-cancer compounds | |
| KR20090040926A (ko) | 암 치료용 배합 생성물 | |
| JP2003533485A5 (https=) | ||
| JP2011522773A5 (https=) | ||
| JP6898329B2 (ja) | 併用療法 | |
| KR20200096788A (ko) | 화학치료법-내성 난소암 또는 유방암 치료에서 parp 억제제의 용도 | |
| JP2019508433A (ja) | Ｌｉｖ１−ａｄｃ及び化学療法剤を用いた併用療法 | |
| US11419862B2 (en) | Quinoline derivative for treatment of nasopharyngeal carcinoma | |
| US20060183765A1 (en) | Methods of treating cancer using an FPT inhibitor and antineoplastic agents | |
| JP2005511663A5 (https=) | ||
| Cheng et al. | Chronic oral etoposide and tamoxifen in the treatment of far‐advanced hepatocellular carcinoma | |
| WO2004032925A1 (en) | Use of imatinib (glivec, sti-571) to inhibit breast cancer resistance protein (bcrp)-mediated resistance to therapeutic agents | |
| Mayerhofer et al. | Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy | |
| AU2007201079A1 (en) | Methods of treating cancer using an FPT inhibitor and antineoplastic agents | |
| MX2007013830A (es) | Terapia de combinacion. | |
| JP2020528418A (ja) | ＢＥＴ阻害剤及びＢｃｌ−２阻害剤を用いた併用療法 | |
| KR20050116166A (ko) | 이리노테칸의 저항성 유방암 치료용 용도 | |
| CN120154734A (zh) | 维奈克拉联合瑞戈非尼在治疗急性髓系白血病中的应用 | |
| Von Pawel | Topotecan (Hycamtin®): potent cytostatic action by selective topoisomerase I inhibition | |
| Board et al. | COI |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |